Skip to main content
Erschienen in: Comparative Clinical Pathology 4/2017

16.06.2017 | Brief Communication

Are surface markers of cancer stem cells reliable factors for cancer treatment follow-up?

verfasst von: Farzaneh Bozorg-Ghalati, Mehdi Hedayati, Mehdi Dianatpour

Erschienen in: Comparative Clinical Pathology | Ausgabe 4/2017

Einloggen, um Zugang zu erhalten

Abstract

Recent studies have explained that cancer stem cells (CSCs) can both instigate and maintain tumours. As a result, they are a good choice for targeted therapy in the treatment of aggressive cancers, and their long-term assessment is essential for the follow-up of therapeutic agent efficacy. However, several studies have revealed that their detection on the basis of surface markers is challenging. In this area, there are two main questions. First, why are surface markers of the CSCs so difficult to detect in in vitro studies? Second, are CSCs’ surface markers reliable factors when assessing cancer treatment efficacy? In order to consider these questions, we made three assumptions: (1) CSCs can grow in environmental conditions and in vitro studies, (2) stress exists within in vitro conditions, and (3) isotope diversity in surface markers might lead to problems in reliable identification.
Literatur
Zurück zum Zitat Bozorg-Ghalati F, Hedayati M (2015) Relationship between PI3K mutation and sodium-iodide symporter in anaplastic thyroid carcinoma. American J Cancer Sci 4:63–77 Bozorg-Ghalati F, Hedayati M (2015) Relationship between PI3K mutation and sodium-iodide symporter in anaplastic thyroid carcinoma. American J Cancer Sci 4:63–77
Zurück zum Zitat Bozorg-Ghalati F, Hedayati M (2016) BRAF mutation and its effects on radioiodine uptake in patients with anaplastic thyroid carcinoma. American J Cancer Sci 5(1):22–33 Bozorg-Ghalati F, Hedayati M (2016) BRAF mutation and its effects on radioiodine uptake in patients with anaplastic thyroid carcinoma. American J Cancer Sci 5(1):22–33
Zurück zum Zitat Bozorg-Ghalati F, Hedayati M, Dianatpour M (2017) CD133 as a biomarker of thyroid cancer stem cells. Int J Curr Res 9(5):51284–51291. Bozorg-Ghalati F, Hedayati M, Dianatpour M (2017) CD133 as a biomarker of thyroid cancer stem cells. Int J Curr Res 9(5):51284–51291.
Zurück zum Zitat Haghpanah V, Fallah P, Naderi M, Tavakoli R, Soleimani M, Larijani B (2016) Cancer stem-like cell behaviour in anaplastic thyroid cancer: a challenging dilemma. Life Sci 1(146):34–39CrossRef Haghpanah V, Fallah P, Naderi M, Tavakoli R, Soleimani M, Larijani B (2016) Cancer stem-like cell behaviour in anaplastic thyroid cancer: a challenging dilemma. Life Sci 1(146):34–39CrossRef
Zurück zum Zitat He QZ, Luo XZ, Wang K, Zhou Q, Ao H, Yang Y, Li SX, Li Y, Zhu HT, Duan T (2014) Isolation and characterization of cancer stem cells from high-grade serous ovarian carcinomas. Cell Physiol Biochem 33:173–184CrossRefPubMed He QZ, Luo XZ, Wang K, Zhou Q, Ao H, Yang Y, Li SX, Li Y, Zhu HT, Duan T (2014) Isolation and characterization of cancer stem cells from high-grade serous ovarian carcinomas. Cell Physiol Biochem 33:173–184CrossRefPubMed
Zurück zum Zitat Liu R, Shen Y, Nan K, Mi B, Wu T, Guo J, Li M, Lv Y, Guo H (2015) Association between expression of cancer stem cell markers and poor differentiation of hepatocellular carcinoma: a meta-analysis (PRISMA). Medicine (Baltimore) 94(31):e1306CrossRefPubMed Liu R, Shen Y, Nan K, Mi B, Wu T, Guo J, Li M, Lv Y, Guo H (2015) Association between expression of cancer stem cell markers and poor differentiation of hepatocellular carcinoma: a meta-analysis (PRISMA). Medicine (Baltimore) 94(31):e1306CrossRefPubMed
Zurück zum Zitat Lobo NA, Shimono Y, Qian D, Clarke MF (2007) The biology of cancer stem cells. Annu Rev Cell Dev Biol 23:675–699CrossRefPubMed Lobo NA, Shimono Y, Qian D, Clarke MF (2007) The biology of cancer stem cells. Annu Rev Cell Dev Biol 23:675–699CrossRefPubMed
Zurück zum Zitat Marhaba R, Klingbeil P, Nuebel T, Nazarenko I, Buechler MW, Zoeller M (2008) CD44 and EpCAM: cancer-initiating cell markers. Curr Mol Med 8(8):784–804CrossRefPubMed Marhaba R, Klingbeil P, Nuebel T, Nazarenko I, Buechler MW, Zoeller M (2008) CD44 and EpCAM: cancer-initiating cell markers. Curr Mol Med 8(8):784–804CrossRefPubMed
Zurück zum Zitat McCord AM, Jamal M, Shankavaram UT, Lang FF, Camphausen K, Tofilon PJ (2009) Physiologic oxygen concentration enhances the stem-like properties of CD133+ human glioblastoma cells in vitro. Mol Cancer Res 7:489–497CrossRefPubMedPubMedCentral McCord AM, Jamal M, Shankavaram UT, Lang FF, Camphausen K, Tofilon PJ (2009) Physiologic oxygen concentration enhances the stem-like properties of CD133+ human glioblastoma cells in vitro. Mol Cancer Res 7:489–497CrossRefPubMedPubMedCentral
Zurück zum Zitat Norton K-A, Popel AS (2014) An agent-based model of cancer stem cell initiated avascular tumour growth and metastasis: the effect of seeding frequency and location. J R Soc Interface 11:640–743CrossRef Norton K-A, Popel AS (2014) An agent-based model of cancer stem cell initiated avascular tumour growth and metastasis: the effect of seeding frequency and location. J R Soc Interface 11:640–743CrossRef
Zurück zum Zitat Plaks V, Kong N, Werb Z (2015) The cancer stem cell niche: how essential is the niche in regulating stemness of tumour cells? Cell Stem Cell 16(3):225–238CrossRefPubMedPubMedCentral Plaks V, Kong N, Werb Z (2015) The cancer stem cell niche: how essential is the niche in regulating stemness of tumour cells? Cell Stem Cell 16(3):225–238CrossRefPubMedPubMedCentral
Zurück zum Zitat Shigdar S, Qiao L, Zhou SF, Xiang D, Wang T, Li Y, Lim LY, Kong L, Li L, Duan W (2013) RNA aptamers targeting cancer stem cell marker CD133. Cancer Lett 330(1):84–95CrossRefPubMed Shigdar S, Qiao L, Zhou SF, Xiang D, Wang T, Li Y, Lim LY, Kong L, Li L, Duan W (2013) RNA aptamers targeting cancer stem cell marker CD133. Cancer Lett 330(1):84–95CrossRefPubMed
Zurück zum Zitat Waldron NN, Vallera DA (2013) An old idea tackling a new problem: targeted toxins specific for cancer stem cells. Antibodies 2:82–92CrossRef Waldron NN, Vallera DA (2013) An old idea tackling a new problem: targeted toxins specific for cancer stem cells. Antibodies 2:82–92CrossRef
Zurück zum Zitat Wang L, Huang X, Zheng X, Wang X, Li SH, Zhang L, Yang Z, Xia Z (2013) Enrichment of prostate cancer stem-like cells from human prostate cancer cell lines by culture in serum-free medium and chemo radiotherapy. Int J Biol Sci 9(5):472–479CrossRefPubMedPubMedCentral Wang L, Huang X, Zheng X, Wang X, Li SH, Zhang L, Yang Z, Xia Z (2013) Enrichment of prostate cancer stem-like cells from human prostate cancer cell lines by culture in serum-free medium and chemo radiotherapy. Int J Biol Sci 9(5):472–479CrossRefPubMedPubMedCentral
Zurück zum Zitat Yu Y, Flint A, Dvorin EL, Bischoff J (2002) AC133-2, a novel isoform of human AC133 stem cell antigen. J Biol Chem 277(23):20711–20716CrossRefPubMed Yu Y, Flint A, Dvorin EL, Bischoff J (2002) AC133-2, a novel isoform of human AC133 stem cell antigen. J Biol Chem 277(23):20711–20716CrossRefPubMed
Zurück zum Zitat Zhang D, Sun B, Zhao B, Ma Y, Ji R, Gu Q, Dong X, Li J, Liu F, Jia X, Leng X, Zhang C, Sun R, Chi J (2014) Twist1 expression induced by sunitinib accelerates tumor cell vasculogenic mimicry by increasing the population of CD133+ cells in triple-negative breast cancer. Mol Cancer 13:207–221CrossRefPubMedPubMedCentral Zhang D, Sun B, Zhao B, Ma Y, Ji R, Gu Q, Dong X, Li J, Liu F, Jia X, Leng X, Zhang C, Sun R, Chi J (2014) Twist1 expression induced by sunitinib accelerates tumor cell vasculogenic mimicry by increasing the population of CD133+ cells in triple-negative breast cancer. Mol Cancer 13:207–221CrossRefPubMedPubMedCentral
Metadaten
Titel
Are surface markers of cancer stem cells reliable factors for cancer treatment follow-up?
verfasst von
Farzaneh Bozorg-Ghalati
Mehdi Hedayati
Mehdi Dianatpour
Publikationsdatum
16.06.2017
Verlag
Springer London
Erschienen in
Comparative Clinical Pathology / Ausgabe 4/2017
Print ISSN: 1618-5641
Elektronische ISSN: 1618-565X
DOI
https://doi.org/10.1007/s00580-017-2504-5

Weitere Artikel der Ausgabe 4/2017

Comparative Clinical Pathology 4/2017 Zur Ausgabe

Neu im Fachgebiet Pathologie

Open Access 21.02.2024 | Fettleber | Originalien

Herausforderungen der Automation bei der quantitativen Auswertung von Leberbiopsien

Automatische Quantifizierung von Leberverfettung

21.02.2024 | Thrombozytopenie | CME

Knochenmarkhistologie bei Zytopenien

Beitrag zur hämatologischen Differenzialdiagnostik

Open Access 19.02.2024 | Künstliche Intelligenz | Originalien

Die Modelltransferierbarkeit von KI in der digitalen Pathologie

Potenzial und Realität